PTPI - Rasio utang marang kapitalisasi buku Petros Pharmaceuticals Inc

Logo grafis Petros Pharmaceuticals Inc (PTPI)

Heavy pressure from generics and digital services is increasing the debt risks of Petros Pharmaceuticals (PTPI), which, when reviewing the history of debt-to-capitalization ratios on GURU.Markets, is evident in the value of 0.00. Optimization is possible through closed B2B contracts with pharmacies and transitioning drugs to over-the-counter status, despite strict FDA oversight and current instability in the customer base.

PTPI (Petros Pharma) riwayat Utang marang nilai buku saka 04.07.2022 nganti 28.06.2025
Barang utama Petros

Petros Pharmaceuticals is investing in eco-friendly drug synthesis and zero-waste technologies. This indicator measures the proportion of debt relative to equity, neutralizing the time lag of quarterly reporting. A declining curve indicates strengthening financial stability, whereas an increase signals over-leverage. By analyzing the ratio of financial liabilities to book capitalization, the investor assesses liquidity risk. The trend of the line determines the balance between conservatism and growth rates.

Pesaing Petros Pharmaceuticals

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik GLPG (Galapagos N.V.)|ANIP: Rasio utang marang kapitalisasi buku|MNKD - Utang-utang marang nilai buku|Utang marang nilai buku Amphastar Pharmaceuticals AMPH|PCRX - Utang marang modal buku|Utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku AQST (Aquestive Pharma)|Utang-utang marang nilai buku SCPH|Tectonic Therapeutic, Inc. (TECX) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik TNXP (tonixpharma.com)|China SXT Pharmaceuticals, Inc. (SXTC) - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku Eupraxia Pharmaceuticals, Inc. EPRX|BHST (BioHarvest) - Utang-utang marang kapitalisasi buku|Invizyne (EXOZ) - Utang-utang marang nilai buku|ORMP - Utang marang nilai buku|ENTX (Entera Bio) - Utang marang modal buku|HYFT - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik ABVC|Cumberland Pharma - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku QNTM (Quantum BioPharma Corp)|Rasio utang marang kapitalisasi buku FGEN|TELO - Utang-utang marang aset resik|Utang marang nilai buku Rani Therapeutics Inc (RANI)|SNYR: Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku rallybio.com (RLYB)|Lexaria Bioscience Corp. (LEXX) - Rasio utang-utang marang kapitalisasi buku|PULM - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik Pheton|Utang-utang marang kapitalisasi buku APM|Utang-utang marang kapitalisasi buku LYRA (Lyra Therapeutics Inc.)|Rasio utang marang kapitalisasi buku Impact BioMedical Inc|TNF Pharmaceuticals Inc. - Rasio utang marang aset resik|YCBD: Rasio utang marang kapitalisasi buku|PRFX - Utang marang nilai buku|CYTO: Utang-utang marang kapitalisasi buku|Lipella Pharmaceuticals Inc (LIPO) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku OPTN|Utang marang nilai buku Pieris Pharma|Procaps Group S.A. - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku qlsyy.net QLI|Utang marang nilai buku SLRN (ACELYRIN)|TFFP - Utang-utang marang kapitalisasi buku